Dichloromethane → Pyrazine-2-carboxamide hydrochloride

(R)-tert-Butyl 1-(3-(pyrazine-2-carboxamido)-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-3-ylcarbamate (0.120 g, 0.237 mmol) was placed in DCM (3 mL) at room temperature. TFA (1 mL) was then added, and the reaction was stirred at room temperature for 1 hour. The reaction was then concentrated to dryness to give the crude product, which was purified C-18 reverse phase flash chromatography (Biotage SP4 unit, C-18 25M column, 0-50% CH3CN/water gradient; 25 CV). The purified product was then dissolved in DCM (with minimal MeOH to aid solubility) and added dropwise to a stirring solution of 1M HCl in ether. The resulting solid was filtered, dried and collected to give (R)—N-(4-(3-aminopiperidin-1-yl)-5-(trifluoromethyl)-1H-pyrrolo[2, 3-1)]pyridin-3-yl)pyrazine-2-carboxamide hydrochloride (0.071 g, 62% yield). 1H NMR (400 MHz, D2O) δ 8.84 (s, 1H), 8.59-8.59 (m, 1H), 8.52-8.52 (m, 1H), 8.31 (s, 1H), 7.79 (s, 1H), 3.62-3.54 (m, 1H), 3.37-3.33 (m, 1H), 3.00-2.92 (m, 3H), 2.04-2.01 (m, 1H), 1.85-1.72 (m, 1H), 1.71-1.66 (m, 1H), 1.50-1.40 (m, 1H); LCMS (APCI+) m/z 406 (M+H)+.

1. concentrationThe reaction was then concentrated to dryness
2. customto give the crude product, which
3. customwas purified C-18 reverse phase flash chromatography (Biotage SP4 unit
4. dissolutionThe purified product was then dissolved in DCM (with minimal MeOH to aid solubility)
5. additionadded dropwise to a stirring solution of 1M HCl in ether
6. filtrationThe resulting solid was filtered
7. customdried
8. customcollected

ORD record

ord-690db339e9564f9a98061d2c3916756f

Source dataset

uspto-grants-2013_10

DOI

10.6084/m9.figshare.5104873.v1

Patent number

US08545897B2